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This paper summarizes experimental data and theoretical con- are the level of sensitivity that is deemed relevant for the study
siderations, that are important for the measurement of P-glyco- and the practicability and reproducibility of the methodologyprotein (Pgp) function in acute myeloid leukemia (AML). The in the local clinical and laboratory setting. Three useful goalsdata are presented in subdivisions based on the techniques
to be considered are:used, which will facilitate finding specific information. Based
on our extensive experience with Pgp analysis, which includes (1) To identify those AMLs with the highest expression of Pgp.
radioactive assays, flow cytometry and fluorescence
A minority of de novo AML samples (20% at most10) willmicroscopy, we recommend a flow cytometry-based assay,
have Pgp expression which is clearly higher than the bulkthat measures the effect of 2 mM PSC 833 on rhodamine 123
(R123) accumulation as the most practical and sensitive func- of samples. This allows the fairly simple categorization of
tional Pgp test. In combination with the flow cytometric AMLs as Pgp-negative (which actually means Pgp
measurement of Pgp using an antibody against an extracellular expression below a certain level) or Pgp-positive.
epitope (eg MRK16), this offers a sensitive and reproducible (2) To aim at classifying the AMLs on a scale of Pgp
method for Pgp detection in AML, which is also rapid and prac-
expression, which in principle may be translated into antical. Furthermore, an R123 accumulation assay is specific for
effect of the drug transporter molecules on the intracellularPgp, because R123 is transported much less efficiently by the
multidrug resistance protein (MRP) than by Pgp. Another probe concentration of drug.10
of similar sensitivity and specificity is 3,39-diethyloxacarbocy- (3) To determine the Pgp expression in a particular subpopul-
anine iodide. Alternatively, especially for the analysis of small ation of cells, eg CD34+ cells instead of or in addition to
numbers of cells (for example sorted subpopulations of leu- the whole population mean.kemic cells), convenient and sensitive procedures are being
developed by using DNA-binding Pgp substrates which remain The following discussion of detection methods will be in the
fixed in the nuclei of the cells upon formaldehyde exposure for light of these goals. Dealing with the same questions, the mer-quantitative fluorescence laser scanning microscopy with
its of different Pgp detection methods have been discussed inimage analysis. Less experimental data have been published
a more general way previously.12to establish the optimal conditions for dual parameter flow
cytometry (Pgp function, in eg Pgp+ or CD34+ cells). However,
laboratories with flow cytometry experience will be able to
implement this useful option to analyze subpopulations of
Materials and methodscells.
Keywords: P-glycoprotein; multidrug resistance; leukemia;
PSC833; rhodamine 123 All cell lines and treatment of AML samples and other
methods have been extensively described in our earlier pap-
ers.1–10 Additional specific details are given when considered
Introduction useful, in the Results section.
It is the purpose of this paper to describe our experience with
assays for the P-glycoprotein (Pgp)-mediated multidrug resist- Fluorescence laser scan microscopy
ance (MDR) phenotype in adult acute myeloid leukemia
(AML). The emphasis is on the measurement of Pgp function, Cells were incubated with daunorubicin (concentration range
in comparison with measurements of Pgp protein expression. 0.05–4 mM) for 75 min at 37°C in medium with 10% fetal
Measurement of ‘Pgp function’ or ‘activity’ implies the assess- calf serum (FCS) and 20 mM Hepes (pH = 7.4) as described
ment of a drug (or dye) transport-related parameter, such as previously.1–3 About 0.3 × 106 KB cells or 0.6 × 106 leukemic
uptake, efflux, steady-state accumulation or intracellular dis- cells per ml were incubated with regular shaking. After incu-
tribution. Our experience is built upon extensive comparison bation the cells were washed twice with ice-cold phosphate-
of methods to determine Pgp MDR in tumor cell lines, also buffered saline (PBS) and cytocentrifuged for 5 min at 350
with low levels of Pgp/MDR1 expression,1–6 experiments and r.p.m. on slides precoated with 0.1% bovine serum albumin
model calculations intended to understand the kinetics of Pgp- solution. Per cytospin 100 ml containing 35 000 KB cells or
mediated daunorubicin transport7,8 and the application of this 80 000 leukemic cells were used. After spinning, the cells
knowledge to measure Pgp in human AML.9–11 We emphasize were immediately fixed for 5 min with 3.6% formaldehyde
the reasons for choosing certain methods above others and solution at room temperature and washed with water. Excess
when appropriate refer to related methods used by other water was removed with tissue and the spins were dried hori-laboratories. zontally in the dark.
Criteria that need to be determined before starting a study Recording of the fluorescence was done initially on a Zeiss
into the clinical relevance of Pgp for chemotherapy resistance laser scanning microscope 41 (Carl-Zeiss, Oberkochen,
Germany) using the Argon laser providing a 488 nm beam.
Emission was measured at wavelengths longer than 515 nm.Correspondence: HJ Broxterman, Dept Medical Oncology, BR 232,
A 63× antiflex Neoflar objective (oil immersion) with an n.a.AZVU, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Received 12 August 1996; accepted 20 December 1996 of 1.25 (Carl-Zeiss) was used, which corresponds to a pixel-
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to-pixel distance of 0.3 mm at the cellular level. Analysis of expression.9 It appeared that the binding of MRK16 to
these cells was not saturable up to 100 mg/ml at 0°C orthe images was done with a Kontron Image Processing System
(IPS, Kontron Bindanalyse, Eching, Germany). During this room temperature. However, for KB8 and KB8-5 cells a
ratio of the mean fluorescence of MRK16 divided bystudy the analysis was continued on a new inverted confocal
laser scanning microscope TCS 4D (Leica, Heidelberg, isotype-matched control (with FITC-labelled second
antibody) was obtained upon the use of 25 mg/ml MRK16Germany) equipped with an Ar/Kr laser. A 40×/1.00–0.50 or
63×/1.40 oil lens was used. Scanning, image processing and (60 min labelling, room temperature) which allowed suf-
ficient resolution to measure Pgp expression over themicroscope control were done using an OS9 minicomputer.
Quantification of the images was done with Leica Q500MC whole range as occurring in AML (see Table 1 and Ref.
10).QWin version v01.00. Fluorescence of daunorubicin was
measured in at least 100–200 cells on three to four images (2) This ratio was higher when a FACSCalibur was used rather
than a FACScan with the same labeling procedure (seefrom two cytospins. The background (from an area between
the cells) was subtracted and the fluorescence divided by the Table 1). A further increase in sensitivity can be obtained
by using phycoerythrin (PE) instead of FITC label.17nuclear area was calculated. Dead cells, based on morpho-
logical appearance and very high fluorescent nuclei, were (3) We have seen that different batches of isotype control anti-
body resulted in different fluorescence in AMLs but not inexcluded. The linearity of nuclear fluorescence/area with dau-
norubicin concentration was extensively tested on both sys- the KB cell lines. Therefore, the latter cannot be used to
select for such differences. The use of high concentrationstems with identical results. It is shown only for the Leica sys-
tem. of antibody requires the selection of a batch of isotype
control antibody which has a low background. In
addition, we ran AML samples without isotype antibody
(buffer only) to track anomalous background binding. OnResults
the other hand, a difference between lots of second anti-
body (rabbit-anti-mouse-FITC) can be monitored in thePgp protein: immunocytochemistry
control cell lines.
(4) Others have advocated not only the use of high concen-Initially we focused on the use of immunocytochemistry for
trations of primary antibody, but also of the second anti-Pgp detection in AML for the obvious reason of simplicity and
body,18 or the use of a biotin-streptavidin step17 in orderthe possibility of determining heterogeneity in expression. We
to be able to measure Pgp in blood cells.18mainly used the monoclonal antibodies JSB-1, C219, MRK16
(5) The application of neuraminidase to unmask MRK16 epi-and occasionally 4E3 or C494 on acetone-fixed cytospins with
topes in AML has not been useful in our hands.9,10peroxidase or alkaline phosphatase-based color development.
(6) For the interpretation of the results obtained with flowHowever, even with a double APAAP staining (see Ref. 11)
cytometry, in some studies, Pgp in AML was expressed aswe were only able to see unequivocal plasma membrane
the percentage of positive cells. In our opinion that is notstaining in very few samples (representing the highest Pgp
adequate because of extensive overlap of isotype-matchedexpressers). Problems with immunocytochemistry are that
and MRK16 distribution in almost all AML samples. Onlysome of the most frequently used anti-Pgp antibodies cross-
in the few percent of highest Pgp expressers was therereact with cytoplasmic proteins13,14 and/or have a low affinity
occasionally an indication of a subpopulation with higherfor their epitope. Therefore, in combination with the low Pgp
expression. The resolution of such subpopulations wasexpression in most clinical tumor samples, a high concen-
better with a rhodamine 123 (R123)-based assay (seetration of antibody or a long incubation period (overnight) is
below).required to detect any signal. Since immunocytochemical Pgp
(7) We have used the concordance with functional Pgp assaysdetection with the presently available antibodies has not yet
as validation of the Pgp specificity of this method10 (seebeen shown to be a sensitive, reproducible method,15 we con-
below). Since the procedure is also rapid (labelling periodsider it premature to use it as a routine technique to estimate
about 2 h) and because of the general availability of flowthe role of Pgp in clinical AML studies. If it is used, strict rules
cytometers and flow cytometric experience in hematolog-for the methodology and interpretation of staining have to be
ical departments, we think that flow cytometric determi-followed. Such general rules which basically apply to each
nation of Pgp is the method of choice for AMLs.quantitative, pathological methodology are summarized by
(8) The relative fluorescence values measured in this way willChan et al.16
Table 1 Pgp expression in KB cells measured with MRK16
Pgp protein: flow cytometry
Cell line No. of FACScan FACS Calibur
experimentsInitial flow cytometry experiments taught us that the staining
of viable cells, requiring the use of an antibody against an
KB3-1 5 1.02 ± 0.02 0.99 ± 0.12outside epitope of Pgp, was superior with regard to sensitivity
KB8 2 3.0 ± 0.8 8.3 ± 1.1and specificity compared to the use of antibodies which KB8-5 6 12.8 ± 4.4 38.1 ± 6.9
required permeabilization of the cells. We have chosen for
the antibody MRK16, but others may be of similar sensitivity. The cells were labelled exactly as described before, with 25 mg/ml
Special attention has been paid to the following points. MRK16 or isotype control antibody for 60 min at room temperature
with FITC-labelled second antibody.10 Samples were run on a(1) We have optimized the flow cytometric Pgp assay by FACSscan or on a FACS Calibur and FL1 was recorded (the same
titrating MRK16 using a cell line panel with no Pgp (KB3- samples on two occasions). Data are ratios ± s.d. of the mean flu-
1), low (about 20000 Pgp molecules per cell; KB8) and orescence of MRK16 divided by isotype-matched control antibody
labelled cells.high (about 200000 Pgp molecules per cell; KB8-5)
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not automatically be comparable at different institutes (or strates needed for the transport process (ATP) need to be well
conserved during the entire procedure.20 Special attention hasinstruments); such concordance will be achieved by cali-
bration with fluorescent beads or alternatively by compari- been paid to the following points.
son with a Pgp-expressing cell line. In the latter case, it
must be checked whether Pgp expression is stable. For (1) In our procedures we had to assume that the aspiration
of blood or bone marrow from a patient, the immediateexample, the KB8 cells have to be thawed regularly from
stocks (every 3–4 months) or large batches of vials have separation of white cells on a Ficoll gradient according to
standard procedures and subsequent performanceto be frozen to be analyzed together with AMLs, because
they tend to become more resistant upon culture with the of a functional assay will give the correct (in vivo
representative) Pgp activity. We have to assume thisindicated concentration of colchicine (5 ng/ml).19 Unfortu-
nately, there is no central laboratory for the distribution of because there is presently no procedure to measure the
Pgp activity of cells in vivo. Although not investigatedMDR cell lines. However, in Table 2 we show some
examples of cell lines for which the number of Pgp mol- systematically, the use of lysis solution to remove red cells
did not seem to be harmful. Nevertheless, we haveecules per cell has been determined (all by MRK16
binding). A cell line with a low antigen density such as avoided its use.
(2) For reasons of cellular metabolic and membrane integrityKB8 cells must be included as an appropriate control in
AML studies. we prefer to use fresh cells, within a few hours after they
have been taken from the patient. Although not reported in
great detail, some investigators have mentioned that upon
keeping cells at room temperature or 4°C for a prolongedPgp function
time (eg overnight) the drug transport function may
become less (see also below under ‘radiolabelled drugWe have chosen to put much effort into the reliable measure-
ment of Pgp function in AML for a number of practical and assays’). One paper explicity reports results of experiments
designed to study the effect of storage conditions of AMLstheoretical reasons. First, as discussed previously, the
measurement of Pgp protein with antibody-based techniques on drug transport function.21
(3) To ensure uniform conditions after Ficoll separation, weposes inherent problems with the discrimination of back-
ground staining from a low specific signal. This called for an keep the cells at 4°C in medium with 10% fetal calf serum
and 20 mM Hepes (pH 7.4 when at 37°C). Protein in theentirely independent technique to confirm Pgp measurements.
Second, although probably not of major concern, potential medium is probably important for good condition of the
cells and it will help to prevent (lipophilic) drugs fromdifferences in Pgp activity by post-translational modification
of Pgp might exist. Third, the measurement of Pgp drug trans- sticking to plastic or glass tubes.
(4) When not assayed the same day cells are frozen in liquidport function allows estimation of the magnitude of the effect
that Pgp expression may have on the drug accumulation and nitrogen and after thawing they are allowed to rehydrate
and recover for 1–2 h in the same protein-containingby inference on its cytostatic effect.
medium at 37°C.10,17,18 In summary, it is advisable to
assay AMLs for Pgp activity as rapidly as possible and with
as little manipulation as possible, in order to minimize thePgp function: assay conditions
chance that alterations in plasma membranes lead to an
(apparently) altered test result.It is important to keep in mind when performing an assay for
the activity of a drug transporter that one works with viable (5) A further important general point is the use of a concen-
tration of probe (radioactive or fluorescent) low enoughcells. In order not to compromise or alter the function of the
transporter protein not only the epitope of the protein as not to saturate the drug pump; otherwise, relatively small
effects on drug accumulation or efflux will be measuredrecognized by an antibody has to be conserved. In addition,
the complete integrity of the protein, its direct environment despite the presence of pump activity. Saturation kinetics
have not been studied for most probes. Therefore it seems(plasma membrane) as well as the concentrations of co-sub-
safe to use a concentration not higher than needed for the
sensitivity of the assay. For daunorubicin we use 0.5 mM
Table 2 Approximate number of Pgp molecules per cell in a radiolabel assay, but 2 mM in flow cytometric assay.
Saturation begins above 2 mM in low resistant cells
Cell line Pgp (MRK16 Method (KB8).7,8
binding
sites/cell)
Pgp function: radiolabelled drug assaysKB3-1 0 QifikitR,44
KB8 22 500a QifikitR,44
KB8-5 225 000a QifikitR,44 To measure Pgp function in AML analytical methods with the
8226/dox4 262 000a QifikitR,44 sensitivity of radiolabelling or fluorescence are needed. We
2780AD 942 500a QifikitR,44 have used extensively radiolabelled daunorubicin, doxorub-NIH3T3 359b QSC-Microbeads
icin, vincristine and etoposide to characterize and quantifyNIH3T3MDR 55 040b QSC-microbeads
active drug efflux mechanisms in tumor cell lines2,5–7 andHT29/S 3000c QifikitR or [125I-MRK16]
HT29/R 120 000c QifikitR or [125I-MRK16] AMLs.9,10 The following points require special attention.
(1) Although these types of assays may not be generally appli-aMean of two experiments, using monoclonal antibody-labelled
cable in every laboratory and require relatively more cellsbeads for calibration (QifikitR,44).
for an accurate measurement than flow cytometric assaysbRef. 45.
cRef. 46. (in the order of 10 × 106 cells), they do allow, however,
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a highly accurate quantification of the effect of a modu- upon specific storage conditions if this has not been
checked. It may be that these problems are less prominentlator (PSC 833 or other) on the whole population of cells,
without possible problems related to interference with the with some of the more sensitive fluorescent Pgp substrates,
such as rhodamine 123 (R123, see below).fluorescence of the probe.10
(2) We have measured the absolute amount of drug accumu-
lated in AMLs, which we have expressed as pmol/106
cells. This requires an accurate counting of the number of Pgp function: Pgp probes for flow cytometry
cells per assay (usually 0.5–1 × 106 blasts in four-fold).
Alternatively, the protein content of the sample can be Many fluorescent molecules have been shown to be substrates
for Pgp. Criteria for an ideal MDR probe have been recentlydetermined.
(3) In addition, we have measured the mean diameter of the summarized by us.11 The choice of a certain combination of
probe, modulator and assay conditions (concentration, time,blast population and corrected the absolute drug accumu-
lation values for cell volume, normalizing to the mean vol- protein composition, pH etc) will necessarily have to be based
on both theoretical and pragmatic reasons. An important leadume of all samples in the study. Such a normalization was
shown to increase the predictive value of flow cytometric for the use of daunorubicin is that it is an agent used for the
treatment of a certain population of AML patients. However,daunorubicin assessment in cell lines.22 We have
observed significant differences in mean steady-state it became clear that a more sensitive probe was needed to
obtain a more reliable and practical assay. Such an assayaccumulation of vincristine and non-steady-state accumu-
lation of doxorubicin in blast samples from clinically appeared to be a 60–90 min (non-steady-state) accumulation
of R123 (200 ng/ml = 0.5 mM) with and without 2 mM PSC833.responding or refractory AML patients.9 In that study a dif-
ference between mean steady-state daunorubicin accumu- An often-applied R123 efflux assay25 was not chosen by us,
because: (1) we wished to keep the assay as simple as possiblelation between both patients groups was observed, but did
not reach significance. Nevertheless, two other papers (short duration, minimal washing of cells); (2) the accumu-
lation assay appeared sensitive enough to detect Pgp activityreport a significant difference of intracellular daunorubicin
accumulation in AML (by flow cytometry) between in AMLs;10 and (3) an R123 efflux assay is more likely to detect
MRP activity as well.1 A convenient probe of similar sensitivityresponding and refractory patients.23,24 Our data9 sug-
gested that vincristine accumulation was the most as R123 used by others is 3,39-diethyloxacarbocyanine iodide
(DiOC2(3)).17,25 Moreover, DiOC2(3) is not a substrate fordiscriminative MDR parameter.
(4) We have performed measurements of absolute drug MRP (unpublished).
accumulation only with freshly obtained material and not
with material stored overnight or thawed, because we
have seen unexplained increases of drug accumulation Pgp function: Pgp modulators
under such conditions. This increase is not due to an
increased anthracycline binding to DNA in permeable (1) For theoretical reasons, any assay measuring the difference
of cellular probe accumulation with or without a modu-cells, since we had added 0.025% DNAse I during these
assays in order to lower the background. The addition of lator is preferred to an absolute probe accumulation assay.
The latter is much more likely to be influenced by factorsDNAse I is an important improvement in anthracycline
accumulation assays especially for samples with low drug such as DNA content (anthracyclines, other DNA binders),
pH (BCECF-AM), number of mitochondria (R123) plasmauptake. Examples are shown in Table 3 for doxorubicin,
where the accumulation increases upon overnight storage membrane potential (R123, DiOC2(3)), Ca2+ ions (Fluo3-
AM) or other variables than is the effect of a well-chosenunder different conditions. Although the magnitude of the
difference may be higher for non-steady-state (75 min) modulator on basal probe uptake. In addition, the choice
of modulator may allow further discrimination of Pgp anddoxorubicin accumulation than for other drugs, these data
clearly show that one cannot assume a priori that cellular MRP-mediated dye efflux. Organic anions, in particular,
are inhibitors of MRP, but not of Pgp-mediated drugdrug uptake/efflux characteristics are unaltered as long as
cells remain (trypan-blue) viable. Similarly, it cannot be efflux.11
(2) The concentration of the modulator of choice has to beassumed that modulation of drug uptake will be unaltered
Table 3 Non-steady-state doxorubicin accumulation in AML
Patient No. Storage conditions overnightb Doxorubicina Doxorubicina
fresh AML stored AML
1 Blood, room temperature 9 19
1 Medium without serum, room temperature 9 34
2 Blood, room temperature 10 33
2 Medium with 10% FCS, room temperature 10 31
3 Blood, room temperature 8 14.5
3 Blood, 4°C 8 13
3 Medium with 10% FCS, room temperature 8 25
4 Medium with 10% FCS, 4°C 7 13
aDoxorubicin in pmol/106 cells after 75 min accumulation (0.5 mM doxorubicin in medium with 20 mM Hepes, 10% FCS, pH = 7.4 at 37°C).
The incubation medium also contained 0.025% DNAse I to exclude doxorubicin binding to DNA in any dead cells present. Data are means
of at least triplicate samples.
bCells were separated on Ficoll and stored as indicated or stored as whole blood and then separated the next day.
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high enough to block Pgp activity completely, but not too pressing cells.34 A double labelling procedure was also used
to measure the accumulation of daunorubicin (in FL2) inhigh to avoid aspecific effects. Lower concentrations of
Pgp inhibitors are needed to block active efflux com- CD341 and CD34− AML cells.35 The latter is possible because
the antigenic density of CD34 is usually high per cell,pletely in cells with a low Pgp expression level than in
model cell lines with a high expression.26 allowing the resolution of CD34+ and CD34− cells by flow
cytometric labelling with FITC (in FL1). Since in virtually every(3) Regarding the specificity for Pgp, different Pgp modulators
may be Pgp-specific in combination with one probe but AML there is a large overlap of MRK16 and isotype control
distribution as well as for daunorubicin and daunorubicin +not with another. For example, 2 mM PSC833 is Pgp-spe-
cific in combination with a daunorubicin or vincristine PSC 833 (difference in means ,2), daunorubicin is probably
too insensitive a Pgp probe for double labelling procedures.uptake assay, whereas 8 mM verapamil is Pgp-specific only
in the case of daunorubicin.10 For the combination A double labelling procedure with R123 and FITC labels is
impossible and the combination with PE label still requiresR123/PSC833, it is short-term accumulation that provides
Pgp specificity.1,27 Since some MRP-overexpressing cell extensive compensation.25 For that reason, the procedure of
Leith et al17 who used DiOC2(3) combined with PE-labelledlines respond to PSC833, its Pgp specificity is not absolute.
Verapamil may even be less specific in that respect.28 The CD33 or CD34 or MRK16 detection with Texas Red, seems
the preferred method for double labelling procedures. How-absence of a good correlation between the effects of
cyclosporin A (1 or 3 mg/ml) on daunorubicin uptake23,29 ever, the need to work at 4°C in order to prevent efflux of
DiOC2(3) does not allow optimal labelling with MRK16 (seeor DiOC2(3) efflux17 in AML with MRK16 labelling, may
be an indication for a Pgp-independent effect of cyclospo- before). Therefore, there is still a need to develop more con-
venient and sensitive double-labelling procedures.rin A. One other study also reported a good correlation
between an R123/cyclosporin A and a dauno-
rubicin/cyclosporin A assay, but again not with MRK16.30
A suboptimal Pgp analysis, such as representation of the
Pgp protein and function: fluorescence microscopydata as percentage positive cells with a cut-off level of
5%30 or labelling at 4°C,10 might partially contribute to
these observations. In many studies on MDR it has been noted by the authors that
there is not only a decreased net drug accumulation in MDR(4) When applying fluorescence measurements it is necessary
always to be aware of interaction of the modulator with cells, but also a quantitative change in the distribution of the
drug over various subcellular localizations. This phenomenon,the fluorescence of the probe in its cellular environment.
The magnitude and frequency of such potential interac- that has been studied mainly for anthracyclines because of
their favorable fluorescence properties, has not been mechan-tions can first be checked with sensitive tumor cell lines,
where there should be no effect. For example, we have istically explained until now. One of the more favored hypoth-
eses is that cytoplasmic vesicular or vacuolar structures inseen quenching of the R123 fluorescence in some cell
lines by PSC 833, not related to a drug pump. However, MDR cells accumulate more drug than in sensitive cells (or
that there are more such structures), which has been suggestedthe highly favorable properties of R123 as a Pgp substrate
outweigh these effects. to contribute to the resistance by exporting drug from the cell
by exocytotic-like mechanisms.36 However, irrespective of the(5) Another property to be aware of in the design of a Pgp
activity assay is whether the modulator itself is being functional role of cytoplasmic drug stores in the MDR pheno-
type, the phenomenon can be measured as an apparenteffluxed (such as verapamil) or is retained in the cells for
a prolonged time, irrespective of Pgp expression (PSC decrease in anthracycline nuclear/cytoplasmic (N/C) ratio in
MDR cells. We have quantified the N/C ratio by fluorescence833).1,31 In the latter case, the cells cannot be loaded with
dye in the presence of the modulator if subsequently the laser scan microscopy in MDR cell lines and shown that it
correlates with resistance even in very low resistant tumor celldye efflux is to be studied.1
(6) Finally, one has to be aware that the protein concentration lines.4,5 Recently we have shown its applicability in AMLs.9
The method works best for doxorubicin rather than daunorub-and composition of the medium is a determinant of the
magnitude of the effect of many highly protein-binding icin as daunorubicin has a relatively high accumulation in
cytoplasmic structures, which makes the detection of MDR bymodulators.32,33 Thus, a certain value holds only for the
particular medium composition. N/C fluorescence distribution more difficult. The measure-
ment of doxorubicin fluorescence N/C ratios requires immedi-
ate analysis of viable cells, as well as a careful, interactive
delineation of cytoplasmic and nuclear borders in the cellularCombination of Pgp protein and function: flow
cytometry images. The latter, especially, is a tedious and time-consum-
ing procedure for analyzing leukemic cells which generally
have a large nuclear area with little cytoplasm.The combination of functional and protein assays using the
flow cytometer reveals the attractive possibility of measuring Since the availability and possibilities of using fluorescence
laser scan microscopy and image processing are continuouslydifferences in Pgp function in subpopulations of cells, eg
CD34+ cells. Data on the expression of MDR in cell clones increasing in analytical pathology and cytology, we think it
worthwhile to develop a sensitive method for detection of Pgpimportant for the progression of the disease are likely to pro-
vide more relevant information as to the contribution of Pgp function in small numbers of cells, such as, for example,
CD34+/CD38− or CD34+/Thy+ cells. For this purpose we haveto therapy outcome and survival.
In principle, a double-labelling with daunorubicin and anti- modified the N/C ratio measurements described above to
allow a more general application. The criteria that we usedbody, eg MRK16 (with FITC-labelled second antibody) is poss-
ible. We have used such a procedure to detect the effect of for the development of a method for the measurement of Pgp
function by fluorescence laser scan microscopy with digitalPSC 833 on daunorubicin accumulation in Pgp-overexpress-
ing (KB8-5) cells in a mixture with sensitive and MRP-overex- image processing were:
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1115Table 4 Effect of PSC 833 on R123 accumulation and nuclear dau-(1) A pool of probe or drug important for drug cytotoxicity
norubicin fluorescence in KB cells and AMLshould be measured.
(2) Detection of plasma membrane Pgp expression and func-
Cells R123 accumulationa Fluorescence ratioction at the single cell level.
(3) A linear range of measurement.
KB3-1 0.97 ± 0.05b 1.03 ± 0.13 (n = 8)(4) A practical, reproducible protocol.
KB8 1.28 ± 0.14b 1.36 ± 0.38 (n = 8)(5) A sensitivity sufficient to detect KB8 level of Pgp function. KB8-5 11.98 ± 1.91b 4.49 ± 1.23 (n = 8)
AMLd 1.11 ± 0.13 1.16 ± 0.25* (n = 12)Criterium 1 was met by using the principle that DNA-binding
AMLd 1.78 ± 0.28 1.37 ± 0.16 (n = 2)Pgp substrates, such as the anthracycline daunorubicin are
AMLd 2.46 ± 0.59 1.68 ± 0.28* (n = 3)
fixed to their DNA-binding sites upon treatment of the cells
with formaldehyde, whereas cytoplasmic fluorescence is aRatio of 60 min R123 accumulation with/without 2 mM PSC 833.lost.37 In this way the pool of daunorubicin in the nucleus will bData from Ref 1.
be measured, which is the important pool for the cytotoxic cRatio of nuclear daunorubicin fluorescence/area after 75 min incu-
action. After measurement of the nuclear fluorescence a bation with 2 mM daunorubicin with or without 2 mM PSC 833 and
subsequent fixation of the cells on cytospins with 3.6% formal-plasma membrane protein (Pgp) can be stained (MRK16 binds
dehyde; per experiment 100–200 cells were analyzed.to Pgp in formaldehyde-fixed cells) and with appropriate flu-
dFrom 17 AML samples that were measured the R123/PSC 833orescent label and filters and/or compensation, Pgp in the
modulation data were also available; the latter was used to subdiv-
plasma membrane can be quantified in the same single cells ide the AMLs into three groups of samples with a R123 modulation
(criterium 2). We chose to measure the effect of PSC 833 on ,1.5 (n = 12), 1.5–2.0 (n = 2) and .2.0 (n = 3) respectively.
the nuclear daunorubicin fluorescence/area. The linearity of *P , 0.01 (t-test).
the method (criterium 3) was investigated in KB3-1 and KB8-
5 cells (see Figure 1). The application of 1–2 mM daunorubicin
with an intermediate or high R123 modulation (see Table 4).appeared to be a good choice (see Figure 1), because the
Thus, although the method works and we have found highervalues were within a linear range and because the nuclear
modulation of the nuclear daunorubicin fluorescence of indi-fluorescence was high enough to avoid problems with back-
vidual AMLs with high Pgp expression, the resolution of theground from autofluorescence in the nuclei. In KB8-5 cells the
method cannot be considered high enough for a statisticaldaunorubicin fluorescence without PSC 833 was just above
reliable detection of the Pgp function in most AML samplesbackground; however, such a large effect of Pgp expression
in a single experiment by measuring 100–200 cells. Therefore,is rarely or never seen in AMLs. Moreover, the modulation
to meet the criterium of sensitivity we have sought to improveeffect of PSC 833 was 4.5 ± 1.2 in KB8-5 cells (see Table 4)
this method by using better Pgp substrates with fluorescencein good agreement with a factor 3.1 ± 1.2 for modulation of
enhancement upon DNA binding, which can be detected bywhole cell daunorubicin accumulation.1 The method
an argon laser. Such probes are some of the SYTOR live-cellappeared practical because the handling of the cells was sim-
nucleic acid stains,38 which can be used in the same way asple and reproducible and because the fixed cytospins could
described for daunorubicin47 (Molecular Probes, Eugene,be stored at room temperature in the dark for at least a week
OR, USA).without loss of fluorescence (criterium 4). Then, as far as the
sensitivity is concerned (criterium 5) it can be seen from Table
4, that for KB8 cells a modulation value of 1.36 ± 0.38 was
Discussionfound. Such values were also found for some AML samples
In this paper we have attempted to account for our methodol-
ogical choices for the measurement of Pgp-mediated MDR in
AML. Since it is impossible to compare directly all possible
permutations of experimental conditions, antibodies, probes
and modulators our choices are not necessarily the ony poss-
ible or the best way of measuring Pgp MDR. However, regard-
ing our data, together with some other recent methodological
papers,15–17,21 it seems justifiable to draw some general con-
clusions.
• To determine the threshold of sensitivity and reproducibility
of any method a laboratory should use at least one cell line
that is Pgp-negative and one with a very low level of Pgp
expression (10 000–50 000 Pgp molecules per cell, see
Table 2).
• Functional Pgp assays seem to be more sensitive than
presently described immunocytochemical methods. Fore-
most, however, is to realize that working with live cells
accordingly strict protocols for handling the cells must be
Figure 1 Mean nuclear daunorubicin fluorescence/area of 100– followed (do not leave cells at bench in the clinic or in the
200 KB8-5 cells per data point. Cells were incubated for 75 min with centrifuge in the laboratory for a period of time).
various concentrations of daunorubicin with or without 2 mM PSC
• Flow cytometric assays for Pgp function can be combined833. The whole range was measured in three groups (with overlapping
with Pgp measurement in order to be more confident of theconcentrations) in which the instrument settings were held constant.
result. With sensitive probes such as R123, frozen materialBackground (mainly nuclear autofluorescence) is about 30% at 0.5 mM
daunorubicin in KB8-5 without PSC 833. can be used if necessary.
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1116 Table 5 Variation of daunorubicin-related parameters in AML• A probe such as daunorubicin is not sensitive enough to
detect Pgp activity in AML for routine use, because the lev-
Parameter Variationels of Pgp are low.
• Subpopulations of blast cells with higher Pgp activity than
Effect of Pgp-inhibitor on daunorubicin ±30%the population mean exist in some AMLs, but these can only
accumulationbe traced with sensitive functional probes (R123, DiOC2(3)), Absolute daunorubicin accumulation ±300%not with daunorubicin. The complete (immuno) pheno- Daunorubicin IC50 (MTT) ±1500%typical identification of the highest Pgp-expressing subpop- Contribution to response Unknown
ulations in AML and their relevance for tumor behaviour
and prognosis will be a topic for future studies. Data are from the same group of (mainly de novo) AML samples.
We have compared the flow cytometric Pgp activity assays
(R123 and daunorubicin) with radiolabelled accumulation us and showed that the contribution of the N/C distribution
assays for daunorubicin and vincristine. Since we have found difference to resistance is always small compared to the
a high correlation between the effect of PSC 833 on radio- accumulation deficit6 (unpublished).
labelled or fluorescent daunorubicin we feel confident that Second, in a 4-day MTT-based cytotoxicity assay of AML
the latter represents an absolute value for the increase. Upon blasts we saw a variation in the IC50 for daunorubicin of about
blocking Pgp with 2 mM PSC 833 this increase falls within the 15 between individual samples, which is much larger than the
range of a 0–50% increase, in good agreement with two other factor 3 observed in the accumulation test (see Table 5). This
studies.39,40 From the radiolabelled daunorubicin measure- suggests that the IC50 for daunorubicin as measured in an MTT
ments we calculated that the absolute value of (volume- test does not reflect differences in intracellular exposure.
corrected) daunorubicin accumulation was 58 ± 15 pmol/106 However, since it is not known whether an MTT assay for
cells (mean ± s.d., n = 62 leukemias; range 33–91; one daunorubicin has predictive value for treatment outcome in
extreme value of 123 excluded) (incubation 0.5 mM daunorub- AML, it cannot be used at present as a reference value for
icin, medium + 10% FCS, 20 mM Hepes, pH 7.4, 75 min other tests.
37°C). These data allow us to speculate further about the Third, it is possible to calculate a theoretical curve of the
quantitative role Pgp may play in the response of patients with effect of Pgp expression on the intracellular free drug concen-
AML to chemotherapy. The question that has to be addressed tration. Such a curve is shown in Figure 2. It shows that with
is, whether there is any evidence from drug uptake studies increasing Pgp expression (of course) the ratio of intracellular
that a (Pgp-mediated?) decrease of daunorubicin accumu-
lation contributes to the in vivo failure to respond to chemo-
therapy or to short (disease-free) survival of AML patients.
The flow cytometric monitoring of daunorubicin concen-
trations in peripheral blasts and bone marrow cells from AML
patients 1 h after in vivo administration of a daunorubicin-
containing regimen showed a tendency of a higher fluor-
escence (not reaching significance) in cells from patients with
a complete response compared to partial response (but not
compared to no response).41 However, because the fluor-
escence does not reach values as high as after in vitro loading
with 2 mM daunorubicin, the background fluorescence will
play a relatively large role in such ex vivo measurements.
As discussed before, we found a factor three difference in
mean in vitro daunorubicin accumulation in AMLs, which
may or may not be related to a drug pump. However, in the
same population, the effect of blocking the Pgp activity (with
2 mM PSC 833) was a maximal 35% increase of daunorubicin
accumulation, with no apparent differences between cases
Figure 2 The effect of Pgp on the intracellular free daunorubicinwith low or high absolute daunorubicin accumulation. This
(DNR) concentration. The relationship between the ratio of intracellu-suggests that other factors (DNA content, vesicles, other drug lar to outside steady-state free DNR concentration (Ci/C0) and the ratiopumps?) contribute more to total in vitro and probably also in of Pgp-mediated (Vmax/KM) and passive (k) DNR transport at the same
vivo daunorubicin uptake than Pgp does. Nevertheless, in this Ci (for Ci ,, KM) is presented. Vmax is assumed to be proportional to
the number of Pgp molecules per cell. The curve was calculatedcontext we may speculate on the contribution of a 35%
according to a model of passive membrane transport with active Pgp-decrease of the mean total cellular daunorubicin accumu-
mediated efflux.8 In the case of equal contribution of passive and Pgp-lation (the contribution of Pgp) to the daunorubicin concen-
mediated efflux Ci/C0 = 0.5 (indicated with a broken line in the figure).tration at its targets in the relevant cells, the cytotoxicity of The data as measured for KB8 and KB8-5 cells as well as for AML
daunorubicin for the cells and the contribution of dauno- samples are indicated in the Figure. The effect of the Pgp inhibitor
rubicin cytotoxicity to total chemotherapy response or the PSC 833 (2 mM) on the cellular daunorubicin accumulation was
assumed to be equal to the effect on Ci. The number of Pgp moleculesduration of the response.
per KB cell or per AML blast producing the same effect is not necessar-First, if the relative nuclear amount of anthracycline fluor-
ily the same, because k may be different and because KB cells areescence is lower in ‘MDR’ than in ‘sensitive’ leukemic cells,
larger. An AML sample at the right side of the rectangle will have aas has been suggested,9 then a 35% decrease of total cellular decrease of DNR Ci to about 0.65 compared to a Pgp-negative sampledaunorubicin concentration would represent an even larger (Ci = C0). If a subpopulation of cells in such a Pgp-expressing AML
decrease in the nucleus. However, model calculations based sample has double the number of Pgp molecules,10 a significant
further decrease of DNR Ci will result.on fluorescence N/C ratio measurements were performed by
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1117daunorubicin transport by P-glycoprotein of intact cancer cells.drug to extracellular drug (Ci/Co) decreases. Figure 2 further
Eur J Biochem 1992; 207: 567–579.demonstrates that this (Ci/Co) ratio is not only dependent on 9 Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JPA, Eek-Vmax of the active drug transport (which is assumed to be pro- man CA, Kuiper CM, Feller N, van Heijningen THM, Klumper E,
portional to the number of Pgp molecules per cell), but also Pieters R, Lankelma J, Pinedo HM. Functional multidrug resistance
on the ratio of active to passive transport rates. For instance, phenotype associated with combined overexpression of
when the passive transport of a drug (analog) is higher but the Pgp/MDR1 and MRP together with 1-b-D-arabinofuranosylcyto-
sine sensitivity may predict clinical response in acute myeloidactive transport remains the same, the net effect of Pgp will
leukemia. Clin Cancer Res 1995; 1: 81–93.be less. This is probably the case for idarubicin when com-
10 Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Wa¨hrerpared to daunorubicin, explaining the smaller net effect of Pgp
DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Lo¨wen-blockers on idarubicin accumulation in Pgp overexpressing berg B, Schuurhuis GJ. Quality control of multidrug resistance
cells42 and more speculatively perhaps some of its increased assays in adult acute leukemia: correlation between assays for P-
clinical efficacy in AML.43 glycoprotein expression and activity. Blood 1996; 87: 4809–4816.
11 Broxterman HJ, Lankelma J, Pinedo HM. How to probe clinicalFourth, Figure 2 shows the net effect of Pgp expression on
tumour samples for P-glycoprotein and multidrug resistance pro-daunorubicin Ci in the population of AML samples studied by
tein. Eur J Cancer 1996; 32A: 1024–1033.us.10 The highest Pgp-expressing AML shows a net decrease
12 Haber DA. Multidrug resistance (MDR1) in leukemia: Is it time toof Ci to about 0.65, as can be seen on the intersection of the test? Blood 1992; 79: 295–298.
solid line with the right side of the rectangle (effect of Pgp 13 Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene-specific
inhibition is then about 50% increase). Importantly, cells with monoclonal antibody C494 cross-reacts with pyruvate carboxy-
more than the mean of Pgp expression10 will have a signifi- lase. Cancer Res 1994; 54: 1536–1541.
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